Claims for Patent: 8,486,885

Summary for Patent: 8,486,885

Title:	.beta.-arrestin effectors and compositions and methods of use thereof
Abstract:	This application describes a family of compounds acting as .beta.-arrestin effectors. Such compounds may provide significant therapeutic benefit in the treatment of chronic and acute cardiovascular diseases.
Inventor(s):	Yamashita; Dennis (Wayne, PA), Chen; Xiao-Tao (Furlong, PA)
Assignee:	Trevena, Inc. (King of Prussia, PA)
Application Number:	12/647,810
Patent Claims:	1. A peptide or peptide mimetic, comprising the sequence of SEQ ID NO:27. 2. The peptide or peptide mimetic of claim 1, wherein the peptide or peptide mimetic is cyclic. 3. The peptide or peptide mimetic of claim 1, wherein the peptide or peptide mimetic is dimerized. 4. The peptide or peptide mimetic of claim 1, wherein the peptide or peptide mimetic is trimerized. 5. A pharmaceutical composition comprising a peptide or peptide mimetic comprising the sequence of SEQ ID NO: 27 and a pharmaceutically acceptable carrier. 6. The pharmaceutical composition of claim 5, wherein the pharmaceutically acceptable carrier is pure sterile water, phosphate buffered saline or an aqueous glucose, solution. 7. The pharmaceutical composition of claim 5, wherein the pharmaceutical composition comprises the peptide comprising the sequence of SEQ ID NO: 27. 8. The pharmaceutical composition of claim 7, wherein the peptide consists of a sequence of SEQ ID NO: 27. 9. The peptide or peptide mimetic of claim 1, wherein the peptide consists of the sequence of SEQ ID NO:27. 10. The pharmaceutical composition of claim 5, wherein the peptide or peptide mimetic is cyclic. 11. The pharmaceutical composition of claim 5, wherein the peptide or peptide mimetic is dimerized. 12. The pharmaceutical composition of claim 5, wherein the peptide or peptide mimetic is trimerized. 13. The pharmaceutical composition of claim 5, further comprising an additional drug for the treatment of a cardiovascular and/or a cardiorenal disorder, wherein the drug is selected from the group consisting of: a diuretic, a vasodilator, an inotrope, an angiotensin converting enzyme inhibitor, a .beta.-blocker, an angiotensin receptor blocker, and an aldosterone antagonist. 14. The pharmaceutical composition of claim 13, wherein the additional drug is selected from the group consisting of furosemide, nitroglycerin, nitroprusside, brain natriuretic peptide, dobutamine, captopril, enalapril, carvedilol, propranolol, valsartan, candesartan, and spironolactone. 15. A composition comprising a peptide or peptide mimetic comprising the sequence of SEQ ID NO:27. 16. The composition of claim 15, wherein the composition comprises the peptide comprising the sequence of SEQ ID NO: 27. 17. The composition of claim 16, wherein the peptide consists of a sequence of SEQ ID NO: 27. 18. The composition of claim 15, wherein the peptide or peptide mimetic is cyclic. 19. The composition of claim 15, wherein the peptide or peptide mimetic is dimerized. 20. The composition of claim 15, wherein the peptide or peptide mimetic is trimerized.

Details for Patent 8,486,885

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	ZOSTAVAX	zoster vaccine live	For Injection	125123	05/25/2006		2028-12-29